GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioxytran Inc (OTCPK:BIXT) » Definitions » Shiller PE Ratio

Bioxytran (Bioxytran) Shiller PE Ratio : (As of May. 16, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Bioxytran Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Bioxytran Shiller PE Ratio Historical Data

The historical data trend for Bioxytran's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioxytran Shiller PE Ratio Chart

Bioxytran Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Bioxytran Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Bioxytran's Shiller PE Ratio

For the Biotechnology subindustry, Bioxytran's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioxytran's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bioxytran's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Bioxytran's Shiller PE Ratio falls into.



Bioxytran Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Bioxytran's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Bioxytran's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.005/129.4194*129.4194
=-0.005

Current CPI (Mar. 2024) = 129.4194.

Bioxytran Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.458 100.560 -0.589
201409 -7.379 100.428 -9.509
201412 6.000 99.070 7.838
201503 -0.300 99.621 -0.390
201506 -6.000 100.684 -7.712
201509 -0.073 100.392 -0.094
201512 0.000 99.792 0.000
201603 -0.600 100.470 -0.773
201606 -0.300 101.688 -0.382
201609 -0.300 101.861 -0.381
201612 0.000 101.863 0.000
201703 -0.900 102.862 -1.132
201706 -0.300 103.349 -0.376
201709 0.046 104.136 0.057
201712 -0.001 104.011 -0.001
201803 0.000 105.290 0.000
201806 0.000 106.317 0.000
201809 -0.001 106.507 -0.001
201812 -0.003 105.998 -0.004
201903 -0.002 107.251 -0.002
201906 -0.002 108.070 -0.002
201909 -0.010 108.329 -0.012
201912 -0.010 108.420 -0.012
202003 -0.010 108.902 -0.012
202006 -0.010 108.767 -0.012
202009 -0.002 109.815 -0.002
202012 -0.010 109.897 -0.012
202103 -0.020 111.754 -0.023
202106 -0.010 114.631 -0.011
202109 -0.004 115.734 -0.004
202112 -0.010 117.630 -0.011
202203 -0.010 121.301 -0.011
202206 -0.010 125.017 -0.010
202209 -0.001 125.227 -0.001
202212 -0.010 125.222 -0.010
202303 -0.010 127.348 -0.010
202306 -0.010 128.729 -0.010
202309 -0.010 129.860 -0.010
202312 -0.010 129.419 -0.010
202403 -0.005 129.419 -0.005

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Bioxytran  (OTCPK:BIXT) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Bioxytran Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Bioxytran's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioxytran (Bioxytran) Business Description

Traded in Other Exchanges
N/A
Address
75 2nd Avenue, Suite 605, Needham, MA, USA, 02494
Bioxytran Inc is a biopharmaceutical company. The company is engaged in developing anti-necrosis drugs that treat a variety of medical conditions resulting from Ischemia. It is also focusing on the development and commercialization of treatments to prevent catastrophic brain damage resulting from hypoxic conditions following brain stroke. Its product candidate, BXT-25, is an anti-necrosis drug that carries oxygen to tissues when the flow of blood is blocked. Its other drug candidate BXT-252 is a resuscitative agent in a variety of wound healing applications.
Executives
Dale H Conaway director 189 WELLS AVE, NEWTON MA 02459
Alan M Hoberman director 6134 MECHANICSVILLE ROAD, PO BOX 56, MECHANICSVILLE PA 18934
Anders Utter director BIOXYTRAN, INC, 233 NEEDHAM ST., SUITE 300, NEWTON MA 02464
David Platt director, 10 percent owner, officer: CEO 12 APPLETON CIRCLE, NEWTON MA 02459
Hana Chen-walden director 7 RUE ARISTIDE MAILLOL, PARIS I0 75015
Michael Sheikh officer: Chief Communication Officer 1905 S AUDUBON CT, SPOKANE WA 99224
Binder Offer other: No longer 10% owner PASQUALE VIA SETTEMBRIMI 14A, SAN MARIANO 06073, CORCIANO PG ITALY L6 00000
Ola Soderquist 10 percent owner, officer: CFO 47 HAMMOND STREET, UNIT 2, WALTHAM MA 02451
Lawrence W. Bonafide director 78365 HWY 111, SUITE 287, LA QUINTA CA 92253
Nathan Marks director 78365 HWY 111, SUITE 287, LA QUINTA CA 92253
Dave Quincy Farber director, officer: President 78365 HWY 111, SUITE 287, LA QUINTA CA 92253
David Lee director 78365 HWY 111, SUITE 287, LA QUINTA CA 92253
Donita R. Kendig director, officer: Secretary/Treasurer 78365 HWY 11, SUITE 287, LA QUINTA CA 92253
Afcc, Llc 10 percent owner 1621 CENTRAL AVENUE, CHEYENNE WY 82001
Paul W Hai 10 percent owner 20443 TIMBERLINE, BEND OR 97701